Scrub typhus in two COVID-19 patients: a diagnostic dilemma

Chandan Kumar Thakur1, Priyam Batra1, EV Vinayaraj1, K Sreenath1, Nisha Rathor1, Urvashi B Singh1, Ridhima Bhatia1, Ajisha Aravindan2, Naveet Wig3, Randeep Guleria4 & Rama Chaudhry*,1
1Department of Microbiology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, 110029, India
2Department of Anesthesiology, Pain Medicine & Critical Care, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, 110029, India
3Department of Medicine, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, 110029, India
4Department of Pulmonary, Critical Care & Sleep Medicine, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, 110029, India
*Author for correspondence: Tel.: +91 112 659 4795; drramach@gmail.com

The authors describe a case series of co-infection with COVID-19 and scrub typhus in two Indian patients. Clinical features like fever, cough, dyspnea and altered sensorium were common in both patients. Case 1 had lymphopenia, elevated IL-6 and history of hypertension, while case 2 had leukocytosis and an increased liver enzymes. Both patients had hypoalbuminemia and required admission to the intensive care unit; one of them succumbed to acute respiratory distress syndrome further complicated by multiple organ dysfunction syndrome. Seasonal tropical infections in COVID-19 patients in endemic settings may lead to significant morbidity and mortality. Therefore, high clinical suspicion and an early diagnosis for co-infections among COVID-19 patients are essential for better patient management.

First draft submitted: 25 June 2021; Accepted for publication: 19 November 2021; Published online: 19 January 2022

Keywords: acute febrile illness • co-infection • COVID-19 • diagnosis • scrub typhus

The ongoing COVID-19 pandemic, which began in December 2019, has posed a serious public health threat globally due to its varying presentations as well as the difficulty in diagnosis and treatment [1]. COVID-19 has an incubation period of 2–14 days with varying manifestations ranging from asymptomatic to mild fever to severe, fatal pneumonia [2]. Various tropical diseases such as scrub typhus and leptospirosis also have such varied presentations and may present with acute respiratory distress syndrome (ARDS) and multiorgan dysfunction syndrome (MODS), which can mimic the current COVID-19 pandemic in endemic countries such as India. Clinicians must be aware of the presence of scrub typhus in endemic regions especially in the monsoons and post-monsoon season. If diagnosed early, prompt treatment can be initiated for the patient [3]. Here, the authors would like to describe two cases of co-infection with SARS-COV-2 and scrub typhus. This article further attempts to express an opinion on the need to address and timely diagnose cases of co-infection with scrub typhus and COVID-19, especially in endemic areas.

Case presentation

In August 2020, a 55-year-old hypertensive male patient, a resident of Madhya Pradesh (a state in central India), presented to the emergency department with fever, cough, dyspnea and altered sensorium. The patient was a known case of seizure disorder and was diagnosed to have meningoencephalitis and COVID-19 lower respiratory tract infection by cartridge-based nucleic acid amplification test (CBNAAT) (Cepheid’s GeneXpert) in the emergency department. He was admitted to the intensive care unit (ICU) and was started on ceftriaxone, vancomycin and doxycycline, and his anti-hypertensive drugs were continued. Ceftriaxone and vancomycin were added as empiric antibiotic therapy for meningoencephalitis, and doxycycline was added to take care of other pathogens causing atypical pneumonia. The patient had lymphopenia (lymphocyte count: 9%; reference range: 20–40%), decreased albumin level (3 g/dl; reference range: 3.2–4.8 g/dl) and increased IL-6 (27.26; reference range: 5–15 pg/ml).
at the time of admission. He responded well to the treatment and was shifted out of the ICU on day 6. He was successfully discharged after 21 days of admission.

In June 2020, a 35-year-old male, a resident of Delhi (a state in north central India) with no prior comorbidities was brought to the emergency department in altered sensorium with fever, cough and dyspnea for the past week. His laboratory investigations revealed increased liver enzymes (alanine transaminase [ALT]; 95 u/l; reference range: 5–45 u/l; aspartate transaminase [AST]; 51 u/l; reference range: 5–40 u/l; and alkaline phosphatase [ALP]; 587 u/l; reference range: 80–240 u/l) and decreased albumin level (2.8 gm/dl; reference range: 3.2–4.8 gm/dl). The patient had ARDS and was found to be COVID-19 positive by real-time reverse transcription polymerase chain reaction (RT-PCR) [4] in the authors’ institute. The patient was mechanically ventilated in the emergency department and was started on hydroxychloroquine, piperacillin/tazobactam and doxycycline. Hydroxychloroquine was started for COVID management; doxycycline and piperacillin/tazobactam were given empirically for other ARDS-causing atypical pathogens. However, his condition kept deteriorating and on day 6 he was shifted to the ICU, where piperacillin/tazobactam was escalated to meropenem. However, the patient did not respond to treatment and went into multiorgan failure and finally succumbed to the infection on day 14. Detailed clinical features and laboratory investigations of both patients are tabulated in Tables 1 & 2.

Screening for other diseases responsible for febrile illness such as leptospirosis, atypical pneumonia (Mycoplasma pneumoniae, Chlamydia pneumoniae and Legionella pneumophila), rickettsioses (spotted fever and typhus group) and scrub typhus were also performed to rule out other differentials, which are endemic in India. Both patients were serologically tested positive for scrub typhus using IgM enzyme-linked immunosorbent assay (ELISA) (InBios, WA, USA), whereas indirect immunofluorescence assay (IgM IFA) (Fuller Laboratories, CA, USA) for scrub typhus was only positive in case 1. The predetermined cut-offs for ELISA and IFA for scrub typhus were used [5]. However, serological tests for other organisms remained negative (details of tests for other organisms are given in Table 3).

DNA was extracted from EDTA-anticoagulated whole-blood samples of patients with positive serology. Nested PCR assay targeting the 56 kDa type-specific antigen (tsa) gene of scrub typhus was performed [6]. Additionally,

| Table 1. Baseline information for the two patients. |
|-----------------------------------------------|
| Clinical features | Case 1 | Case 2 |
| Age (years) | 55 | 35 |
| Sex | Male | Male |
| Fever | Present | Present |
| Cough | Present | Present |
| Dyspnea | Present | Present |
| Myalgia | Absent | Absent |
| Vomiting | Absent | Absent |
| Diarrhea | Absent | Absent |
| Pulse rate (per min) | 54 | 140 |
| Respiratory rate (per min) | 20 | 38 |
| Blood pressure (mmHg) | 100/58 | 130/90 |
| Oxygen saturation (room air) | 100% | 50% |
| Altered sensorium | Present | Present |
| Duration of hospital stay (days) | 21 | 14 |
| Comorbidities | | |
| Diabetes | No | No |
| Hypertension | Yes | No |
| Bronchial asthma | No | No |
| COPD | No | No |
| Immunocompromised | No | No |
| Cardiovascular diseases | No | No |
| Renal diseases | No | No |
| TB | No | No |
| Malignancy | No | No |

COPD: Chronic obstructive pulmonary disease; TB: Tuberculosis.
## Table 2. Laboratory parameters of the two patients.

| Laboratory parameters | Reference range | Case 1 | Case 2 |
|-----------------------|----------------|--------|--------|
| Hemoglobin            | Female: 11–15 g/dl; male: 13–17 g/dl | 11.2   | 11.1   |
| Red blood cell count  | 3.8–4.8 (10^12/μl) | 3.65   | 3.25   |
| White blood cell count| 4–11 (10^11/μl) | 11.88  | 16.38  |
| Neutrophils           | 40–80 (%) | 82.5   | ND     |
| Lymphocytes           | 20–40 (%) | 9.9    | ND     |
| Monocytes             | 2–10 (%) | 7      | ND     |
| Eosinophils           | 1–6 (%)  | 0.2    | ND     |
| Basophils             | 1–2 (%)  | 0.4    | ND     |
| Platelet count        | 150–400 (10^11/μl) | 262    | 277    |
| Total bilirubin       | 0.3–1.2 mg/dl | 0.4    | 0.7    |
| ALT                   | 5–45 u/l | 24     | 95     |
| AST                   | 5–40 u/l | 34     | 51     |
| ALP                   | 80–240 u/l | 65    | 587    |
| Urea                  | <50 mg/dl | 19     | 53     |
| Creatinine            | 0.5–1.1 mg/dl | 0.6   | 0.6    |
| Sodium                | 132–146 mmol/l | 138   | 137    |
| Potassium             | 3.5–5.5 mmol/l | 4    | 5.2    |
| Total protein         | 5.7–8.2 g/dl | 6     | 5      |
| Albumin               | 3.2–4.8 g/dl | 3      | 2.8    |
| Globulin              | 2.5–3.4 g/dl | 2.9 | 2.2    |
| LDH                   | 140–280 u/l | 304   | ND     |
| IL-6                  | 5–15 pg/ml | 27.26  | ND     |
| Serum ferritin        | 10–291 ng/ml | 220.5 | ND     |

### Co-infections

| Organism                                | Serology                   | Molecular targets, test performed | Ref. |
|-----------------------------------------|----------------------------|----------------------------------|------|
| Scrub typhus IgM ELISA (OD)             | ≥0.89                      |                                  |      |
| Scrub typhus IgM IFA                    | ≥64                        | +                                |      |
| Nested PCR (56 kDa)                     | 483 bp                     |                                  |      |
| Serology for *Rickettsia spp.*, *Leptospira spp.*, *Mycoplasma pneumoniae*, Chlamydia pneumoniae and Legionella pneumophila | Refer to Table 3           | -                                |      |
| Molecular tests for *Rickettsia spp.*, *Leptospira spp.*, *M. pneumoniae* and *L. pneumophila* | Refer to Table 3           | -                                |      |

**ALT:** Alanine transaminase; **ALP:** Alkaline phosphatase; **AST:** Aspartate transaminase; **bp:** Basepair; **ELISA:** Enzyme-linked immunosorbent assay; **ESR:** Erythrocyte sedimentation rate; **IFA:** Indirect immunofluorescence assay; **kDa:** Kilodalton; **LDH:** Lactate dehydrogenase; **ND:** Not done; **OD:** Optical density.

## Table 3. Serological and molecular tests used to rule out other pathogens.

| Organism                                | Serology                   | Molecular targets, test performed | Ref. |
|-----------------------------------------|----------------------------|----------------------------------|------|
| Rickettsia spotted fever and typhus group | IgM IFA (Fuller Laboratories, CA, USA) cut-off 1:64 | gltA gene, real-time PCR | [26] |
| *Leptospira spp.*                       | IgM ELISA (Panbio Pty., Queensland, Australia) cut-off >11 | 16s rRNA, conventional PCR | [27] |
| Atypical bacteria                       |                           |                                  |      |
| *Mycoplasma pneumoniae*                 | IgM ELISA (NovaTec Immunodiagnostica GmbH, Dietzenbach, Germany) cut-off >11 | CARDS toxin gene, real-time PCR | [28] |
| *Chlamydia pneumoniae*                  | IgM ELISA (NovaTec Immunodiagnostica GmbH, Dietzenbach, Germany) cut-off >11 | Not done |      |
| *Legionella pneumophila*                | IgM ELISA (NovaTec Immunodiagnostica GmbH, Dietzenbach, Germany) cut-off >11 | ssrA gene, real-time PCR | [29] |

**ELISA:** Enzyme-linked immunosorbent assay; **IFA:** Indirect immunofluorescence assay.
these samples were screened for other tropical pathogens, including *Rickettsia*, *Leptospira* and atypical bacteria (Table 3). Molecular detection for *Leptospira* spp. by PCR and *Mycoplasma pneumoniae* and *Legionella pneumophila* by real-time PCR were found to be negative. Molecular tests for *Chlamydia pneumoniae* could not be performed. However, nested PCR for *Orientia tsutsugamushi* and real-time PCR for *Rickettsia* spp. were also negative for both cases.

**Discussion**

Scrub typhus is a mite-borne bacterial infection caused by the obligate intracellular organism *Orientia tsutsugamushi*. Annually, one million cases are estimated to occur globally and approximately one billion people are at risk with substantial mortality rates [7]. It is endemic in almost every state of India and accounts for up to 15–30% of all febrile episodes [8]. India is the second most infected country with COVID-19 in the world after the USA [9]. Scrub typhus in India occurs mostly during the rainy season (July to November) and is characterized by myriad clinical manifestations such as fever, headache, rash, myalgia, dyspnea, lymphadenopathy, ARDS and MODS [3]. These symptoms can mimic the clinical symptoms of an ongoing outbreak of COVID-19 in the absence of characteristic eschar. Although the presence of eschar is highly suggestive of scrub typhus, looking for it in COVID-19 patients is difficult, as they require physical separation. Moreover, scrub typhus had not been suspected in these patients; hence, a detailed physical examination was not undertaken by overburdened clinicians in the present epidemic.

Blacksell *et al.* have described the modified scrub typhus infection criteria (mSTIC) for laboratory diagnosis of scrub typhus, which includes qPCR using the *Orientia* spp. 47 kDa *htrA* gene, a single admission IgM IFA titer ≥1:3200, IFA ≥ 1:3200 on admission or fourfold rise to ≥3200 and a combination of PCR and IFA positivity [10]. However, PCR and IFA are expensive and not easily available in the majority of Indian hospitals. Also, the high cost of IFA restricts the determination of end point titers in every positive case. Previous Indian studies have highlighted the fact that while a fourfold increase in antibody titers in paired sera is expected for diagnosis, a prompt diagnosis at the time of admission is required to guide initial treatment. Furthermore, the availability of convalescent sera is limited, as most cases do not come for follow-ups. Hence, following such diagnostic algorithm may not be feasible in the majority of the tertiary care referral hospitals located in India [5,11]. A study from Thailand by Blacksell *et al.* found that an admission diagnosis of scrub typhus at a cut-off OD of 0.5 using ST InBios IgM ELISA corresponds to an IFA reciprocal titer cut-off of ≥1600. The use of 0.5 as the cut-off OD in ELISA was demonstrated to have sensitivity and specificity of 93% and 91%, respectively, and may thus be used as an excellent alternative to the gold standard IFA [12]. Another study from Bangladesh by Blacksell *et al.* concluded that cut-off OD within the range of 0.75–1.25 using InBios ST IgM ELISA was the most suitable cut-off OD for the diagnosis of scrub typhus [10]. In the present study, IgM antibodies against scrub typhus were detected using ELISA (cut-off >0.89) in both patients with OD more than 1.00. However, IFA was positive in only one case. IFA is considered a reference test for the diagnosis of scrub typhus, but commercial IFA slides are coated with only four serotypes: Karp, Kato, Gilliam and Boryong. However, diverse serotypes of *Orientia tsutsugamushi*, which may be missed by IFA, are circulating in the world [13]. A molecular assay such as PCR is usually positive in the first week of disease during rickettsemia. It has low sensitivity beyond the first week of illness [14]. The PCR negativity in these two patients might be attributed to the late course of scrub typhus and the use of antibiotics such as doxycycline during COVID-19 therapy. In addition, it is recommended that a buoyy coat be used due to high sensitivity rather than whole blood for scrub typhus PCR, which might have affected the PCR positivity [15]. The limitation of this study is that the authors were not able to demonstrate a rising antibody titer because of the unavailability of convalescent serum. In addition, they were unable to determine whether the death of one patient in this report was attributed to co-infection or COVID-19 alone, because complications like ARDS and MODS are associated with scrub typhus as well COVID-19.

Scrub typhus is grossly under-reported and underdiagnosed, attributable to the misperception that this disease is only a concern in vigorously forested zones. The clinical presentation often mimics that of other common febrile illnesses that share similar seasonal patterns, such as chikungunya and dengue virus infection, creating a diagnostic dilemma and delay in definitive therapy that may lead to adverse clinical outcomes. Thus, the possibility of the co-existence of scrub typhus with COVID-19 during monsoon and post-monsoon season in endemic settings cannot be ruled out; therefore, it should be looked at cautiously and treated appropriately. Previously, the authors reported mortality in five patients due to scrub typhus during the chikungunya outbreak in the absence of timely suspicion, diagnosis and treatment [16]. A recent case report from Thailand stated that COVID-19 can present as
an acute febrile illness and can be difficult to distinguish from other tropical diseases, particularly when respiratory symptoms are absent [17].

Recent studies have described the co-infection of COVID-19 with other respiratory pathogens like influenza, Mycoplasma pneumoniae, Chlamydia pneumoniae, Legionella pneumophila, Klebsiella pneumoniae, Acinetobacter baumanii, Aspergillus fumigatus [18–23] and Candida auris [24]; however, information related to co-infection of COVID-19 with scrub typhus is lacking. Bacterial co-infections in the presence of viral pneumonia have been shown to be a major cause of morbidity and mortality [25]. Hence, there is a great necessity to include scrub typhus in the differential diagnosis of patients presenting with fever in tropical areas, especially with ARDS and MODS, during the current COVID-19 pandemic.

Conclusion

Scrub typhus is a prominent cause of acute febrile illness in the Asia–Pacific region. The most essential management challenge is the institution of appropriate therapy in a timely and effective manner. During outbreaks of viral fever, scrub typhus cases may get missed due to overlapping clinical presentations. Co-infection with such seasonal tropical infections in endemic settings leads to significant morbidity and mortality. Therefore, high clinical suspicion for co-infections among COVID-19 patients during an early stage of illness and precise diagnosis are essential for better patient management.

**Summary points**

- The authors describe a case report of co-infection with COVID-19 and scrub typhus in two Indian patients.
- Tropical diseases such as scrub typhus also have varied presentations and may present with acute respiratory distress syndrome and multiorgan dysfunction syndrome, which can mimic the current COVID-19 in endemic countries such as India.
- The possibility of the co-existence of scrub typhus with COVID-19 during monsoon and post-monsoon season in endemic settings cannot be ruled out, and therefore it should be looked at cautiously and treated appropriately.
- Bacterial co-infections in the presence of viral pneumonia can result in morbidity and mortality.
- Clinicians must be aware of the existence of scrub typhus with or without COVID-19 in endemic areas, particularly in the absence of eschar.

**Author contributions**

R Chaudhry contributed to the study concept; CK Thakur, R Chaudhry and P Batra searched the literature and obtained the relevant articles; CK Thakur, P Batra and R Chaudhry analyzed the data and wrote the article; UB Singh supervised COVID-19 test performance. CK Thakur performed the serological and molecular tests for scrub typhus and rickettsia; K Sreenath, EV Vinayaraj and N Rathor performed molecular tests for other pathogens; A Aravindan and R Bhatia contributed to sample collection and obtaining relevant clinical information on the patients; N Wig and R Guleria contributed to patient management. All authors approved the final manuscript.

**Acknowledgments**

The authors acknowledge the Indian Council for Medical Research (ICMR) and all of the clinical and laboratory team for their contribution and help in carrying out this study.

**Financial & competing interests disclosure**

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

**Ethical conduct of research**

This study is approved by institute ethical committee (IEC-287/17.04.2020). The authors state that they have obtained written informed consent from the patients for the inclusion of their medical and treatment history within this case series.
References

Papers of special note have been highlighted as: ● of interest

1. World Health Organization. Naming the coronavirus disease (COVID-19) and the virus that causes it (2020). http://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it

2. Li Q, Guan X, Wu P et al. Early transmission dynamics in Wuhan, China, of novel coronavirus – infected pneumonia. N. Engl. J. Med. 382(13), 1199–1207 (2020).

● This article reports an initial assessment of the transmission dynamics and epidemiologic characteristics of novel coronavirus-infected pneumonia.

3. Thakur CK, Chaudhry R, Gupta N et al. Scrub typhus in patients with acute febrile illness: a 5-year study from India. QJM 113(6), 404–410 (2020).

● This paper presents scrub typhus data over 5 years and discusses the clinical and molecular epidemiology of scrub typhus in patients with acute febrile illness from diverse areas of India.

4. Gupta N, Potdar V, Prahara I et al. Laboratory preparedness for SARS-CoV-2 testing in India: harnessing a network of virus research & diagnostic laboratories. Indian J. Med. Res. 151(2), 216–225 (2020).

5. Gupta N, Chaudhry R, Thakur CK. Determination of cutoff of ELISA and immunofluorescence assay for scrub typhus. J. Glob. Infect. Dis. 8(3), 97–99 (2016).

6. Furuya Y, Yoshida Y, Katayama T, Yamamoto S, Kawamura A. Serotype-specific amplification of Rickettsia tsutsugamushi DNA by nested polymerase chain reaction. J. Clin. Microbiol. 31(6), 1637–1640 (1993).

7. Walker DH. Scrub typhus–scientific neglect, ever-widening impact. N. Engl. J. Med. 375(10), 913–915 (2016).

● This article addresses the important aspects of scrub typhus, such as the vector, epidemiology, transmission dynamics, immunopathogenesis and control measures.

8. Devamani CS, Prakash JAJ, Alexander N, Suzuki M, Schmidt WP. Hospitalisations and outpatient visits for undifferentiated fever attributable to scrub typhus in rural South India: retrospective cohort and nested case–control study. PLoS Negl. Trop. Dis. 13(2), e0007160 (2019).

9. WHO. WHO coronavirus disease (COVID-19) dashboard (2020). https://covid19.who.int/

10. Blacksell S, Kingston H, Tanganuchitcharnchai A et al. Diagnostic accuracy of the InBios Scrub Typhus Detect™ ELISA for the detection of IgM antibodies in Chittagong, Bangladesh. Trop. Med. Infect. Dis. 3(3), 95 (2018).

● The accuracy of the InBios Scrub Typhus Detect™ immunoglobulin M enzyme-linked immunosorbent assay was evaluated to establish the optimal optical density cut-off values for the diagnosis of scrub typhus.

11. Koralur M, Singh R, Varma M et al. Scrub typhus diagnosis on acute specimens using serological and molecular assays—a 3-year prospective study. Diagn. Microbiol. Infect. Dis. 91(2), 112–117 (2018).

12. Blacksell SD, Tanganuchitcharnchai A, Nawatsong P et al. Diagnostic accuracy of the InBios Scrub Typhus Detect enzyme-linked immunosassay for the detection of IgM antibodies in northern Thailand. Clin. Vaccine Immunol. 23(2), 148–154 (2016).

13. Stephen S, Gunasekaran D, Anitharaj V. Application of enzyme linked immunosorbent assay (ELISA) and indirect fluorescent antibody test for serodiagnosis of acute scrub typhus in and around Puducherry, India. J. Clin. Diagnost. Res. 12(11), 12–16 (2018).

14. Patricia KA, Hoti SL, Kanungo R, Jambulingam P, Shashikala N, Naik AC. Improving the diagnosis of scrub typhus by combining groEL based polymerase chain reaction and IgM ELISA. J. Clin. Diagnostic Res. 11(8), 27–31 (2017).

15. Kannan K, John R, Kundu D et al. Performance of molecular and serologic tests for the diagnosis of scrub typhus. PLoS Negl. Trop. Dis. 14(11), e0008747 (2020).

16. Chaudhry R, Thakur CK, Gupta N et al. Mortality due to scrub typhus – report of five cases. Indian J. Med. Res. 149(6), 790–794 (2019).

● This study outlines the mortality in five patients due to scrub typhus during the chikungunya outbreak in the absence of timely suspicion, diagnosis and treatment and the need for scrub typhus to be included in the differential diagnosis of patients presenting with acute febrile illness, particularly during viral fever outbreaks.

17. Nanthavichitra S, Prapaso S, Luvira V, Muangnoicharoen S, Leangwutiwong P, Piyaphanee W. Case report: COVID-19 presenting as acute undifferentiated febrile illness – a tropical world threat. Am. J. Trop. Med. Hyg. 103(1), 83–85 (2020).

18. Chen X, Liao B, Cheng L et al. The microbial coinfection in COVID-19. Appl. Microbiol. Biotechnol. 104(18), 7777–7785 (2020).

● This article describes the co-infection of virus, bacteria and fungi with SARS-COV-2, their impact on COVID-19, the reasons for co-infection and the diagnosis to underline the relevance of microbiological co-infection in COVID-19.

19. Chaudhry R, Sreenath K, Vinayaraj EV et al. Mycoplasma pneumoniae coinfection with SARS-CoV-2: a case report. Access Microbiol. 3(3), 000212 (2021).

20. Zhang G, Hu C, Luo L et al. Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan, China. J. Clin. Virol. 127, 104364 (2020).
21. Chaudhry R, Sreenath K, Batra P et al. Atypical bacterial co-infections among patients with COVID-19: a study from India. *J. Med. Virol.* 94(1), 303–309 (2021).

22. Sreenath K, Batra P, Vinayaraj EV et al. Coinfections with other respiratory pathogens among patients with COVID-19. *Microbiol. Spectr.* 9(1), e0016321 (2021).

- This article reports co-infection with COVID-19 and other respiratory pathogens in India.

23. Koehler P, Cornely OA, Böttiger BW et al. COVID-19 associated pulmonary aspergillosis. *Mycoses* 63(6), 528–534 (2020).

24. Chowdhary A, Tarai B, Singh A, Sharma A. Multidrug-resistant *Candida auris* infections in critically Ill coronavirus disease patients, India, April–July 2020. *Emerg. Infect. Dis.* 26(11), 2694–2696 (2020).

25. Guo L, Wei D, Zhang X et al. Clinical features predicting mortality risk in patients with viral pneumonia: the MuLBSTA score. *Front. Microbiol.* 10, 2752 (2019).

26. Stenos J, Graves SR, Unsworth NB. A highly sensitive and specific real-time PCR assay for the detection of spotted fever and typhus group *Rickettsiae*. *Am. J. Trop. Med. Hyg.* 73(6), 1083–1085 (2005).

27. Mérin F, Amouriaux P, Perolat P, Baranton G, Saint Girons I. Polymerase chain reaction for detection of *Leptospira* spp. in clinical samples. *J. Clin. Microbiol.* 30(9), 2219–2224 (1992).

28. Winchell JM, Thurman KA, Mitchell SL, Thacker WL, Fields BS. Evaluation of three real-time PCR assays for detection of *Mycoplasma pneumoniae* in an outbreak investigation. *J. Clin. Microbiol.* 46(9), 3116–3118 (2008).

29. Benitez AJ, Winchell JM. Clinical application of a multiplex real-time PCR assay for simultaneous detection of *Legionella* species, *Legionella pneumophila*, and *Legionella pneumophila* serogroup 1. *J. Clin. Microbiol.* 51(1), 348–351 (2013).